Amplify Weight Loss Drug & Treatment ETF THNR
25.02 USD -0.51 (-2.02%)
Regular-session close
25.02 0.00 0.00%
After hours · Nov 18, 4:10 PM ET
25.02 Day range 25.36
23.40 52-week range 27.94
- YTD
- -0.78%
- 1 year
- -0.78%
News
zacks.com 4 Healthcare ETFs to Tap Into Eli Lilly's Post-Q3 Earnings Rally Eli Lilly's post-Q3 earnings rally highlights its surging drug demand. Discover 4 healthcare ETFs offering LLY exposure.
etftrends.com Eli Lilly, Regeneron Lead Weight-Loss ETF THNR Higher The Amplify Weight Loss Drug & Treatment ETF (THNR) returned 3.2% in October, according to Amplify ETFs. Eli Lilly and Co. (LLY) drove most of that gain, after reporting quarterly results that beat…
etftrends.com What the Holidays Hold for GLP-1 Stocks in THNR The holiday season is almost here and will soon be followed by the annual surge in New Year's resolutions. This will likely drive renewed interest in GLP-1 products, especially as new oral GLP-1…
zacks.com Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss Novo Nordisk's CagriSema delivers 25% weight loss in women, spotlighting three ETFs for diversified exposure to the sector's growth.
zacks.com Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market REX Shares recently launched the REX Peptide ETF (PEPT), a thematic fund offering global exposure to the peptide industry, from drug developers to manufacturers and delivery platforms.
etftrends.com From Laggard to Leader: The Surprising Comeback of Healthcare Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's…
zacks.com Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
etftrends.com Who Are You Calling Passive? Many Index ETFs Dynamically Rebalanced in September There is a myth that index-based ETFs are all static buy-and-hold products that passively track a benchmark. Many people think of indexing through the lens of market-cap strategies like the Vanguard…
etftrends.com NTHM's Index Rebalance Puts Thematic Rotation to Work The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes.…
etftrends.com THNR's Weight-Loss Index Swaps Hims & Hers for Gilead The Amplify Weight Loss Drug & Treatment ETF (THNR) just refreshed its holdings to keep pace with where the weight-loss drug race is heading. Its underlying index, the VettaFi Weight Loss Drug &…
etftrends.com Inside THNR: A Leaner Approach to Weight Loss Investing Demand for GLP-1 weight loss drugs has reshaped the healthcare industry. And ETFs such as the Amplify Weight Loss Drug & Treatment ETF (THNR) give investors a way to access this growing market.
zacks.com Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
etftrends.com Healthcare ETFs: From Broad Exposure to Big Breakthroughs With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive…
zacks.com Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
etftrends.com LLY Clears Major Obesity Trial: Get Exposure in THNR Weight loss drugs have been a big growth area in pharmaceuticals since GLP-1s hit the scene. This booming market has also breathed new life into companies like Eli Lilly (LLY), turning the stock into…
zacks.com GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
etftrends.com Weight Loss ETF THNR Reweights Its Index: What's Up & Down Weight loss pills and treatments have exploded in popularity since GLP-1 drugs hit the market. From Ozempic to Wegovy, those pills have changed the lives of countless people around the world.
seekingalpha.com OZEM Vs. THNR: Which Is The Better ETF In The GLP-1 And Weight Loss Space? I recommend buying the Roundhill GLP-1 & Weight Loss ETF (OZEM) for strategic exposure to the weight loss drug sector. OZEM offers diversified access to leading GLP-1 innovators like Novo Nordisk and…
etftrends.com New Year, New Strategy: Navigating Weight Loss ETFs With the start of 2026, the annual focus on weight loss resolutions presents a timely opportunity for financial advisors to discuss the investment potential of GLP-1 agonists with their clients. This…
